• Home
  • DGCR8 is essential for tumor progression following PTEN loss in the prostate.

DGCR8 is essential for tumor progression following PTEN loss in the prostate.

Author List
Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R
Publication
EMBO reports
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1193281
Publication Year
2015
PubMed ID
26206718
Publication Title
Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R. DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 2015 Sep; 16(9):1219-32.